# QIBA SPECT TC<sup>99m</sup> Biomarker Committee (BC) Call Tuesday, August 11, 2020, 2 PM (CT) *Call Summary*

#### In attendance:

Yuni Dewaraja, PhD (Co-chair)JohnRobert Miyaoka, PhD (Co-Chair)AnneDenis Bergeron, PhDP. Da

John Dickson, PhD Annelise Malkus, PhD P. David Mozley, MD A. Hans Vija, PhD Brian Zimmerman, PhD **RSNA Staff** Joe Koudelik Julie Lisiecki

# Moderator: Dr. Miyaoka

# SPECT TC<sup>99m</sup> Profile Public Comment – Feedback Resolution Update

- Dr. Miyaoka reviewed two additional AAPM comments that were addressed
- Profile v 1.0 is now complete and available for use on the **QIBA wiki**
- Dr. Miyaoka to provide an updated copy of the <u>comment resolution sheet</u> for posting to the QIBA wiki
- Changes have been saved and a copy with all changes is available on the Dropbox

### Next steps discussed:

- Possibility of a feasibility test using the Profile checklist; at least two sites would be needed
- Dr. Miyaoka volunteered his team to test the checklist at the University of Washington
- Pharma and CRO contacts were encouraged to review the checklist and provide feedback
- Dr. Mozley said he has finished testing the Profile in a pharma trial using four phantoms, but data will not be available for release for some time, due to legal agreements
  - Test-retest subject data will eventually be available; five subjects were scanned twice, in addition to small specially sized bottle phantoms
  - NIST protocols were followed for radioactivity and dose calibration re: the phantom fill solution
- Dr. Mozley also mentioned two potential NIH proposals that could yield additional data
- Dr. Zimmerman reminded anyone doing testing to make certain to use NIST or NIST-traceable phantoms / solutions and to document everything carefully, keeping track of any anomalies
  - He also mentioned that when doing transfers between geometries or making dilutions; any changes/modifications should be well documented to assure traceability
- Though additional scanning and feasibility testing would be desirable, the group acknowledged that it may be difficult, due to pandemic limitations on research activities
- Dr. Dickson suggested considering a future Profile for lutetium, as there is much interest in this area
- Dr. Miyaoka inquired about the proposed PET Cardiac Profile
  - Although no progress has been reported, Dr. Smith was recommended as a contact for follow up
- Amendments to existing Profiles were another option discussed, as the FDG-PET BC has suggested adding appendices for additional PSMA and Gallium tracers
- More discussion regarding these topics will likely occur at the upcoming Nuclear Medicine Coordinating Committee call on August 27<sup>th</sup> at 2 pm CT
- A future call for the TC<sup>99m</sup> BC may be planned to discuss Dr. Mozley's research and site Profile feedback when data are available
- Dr. Mozley reminded all members to utilize the Profile in their own work and to encourage colleagues to do so as well

### Next BC call – TBD, if a call is needed